Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/29409
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLau, D-
dc.contributor.authorCorrie, PG-
dc.contributor.authorGallagher, FA-
dc.date.accessioned2024-07-25T14:47:58Z-
dc.date.available2024-07-25T14:47:58Z-
dc.date.issued2022-09-19-
dc.identifierORCiD: Doreen Lau https://orcid.org/0000-0002-7623-2401-
dc.identifierORCiD: Pippa G Corrie https://orcid.org/0000-0003-4875-7021-
dc.identifierORCiD: Ferdia A Gallagher https://orcid.org/0000-0003-4784-5230-
dc.identifiere004708-
dc.identifier.citationLau, D., Corrie, P.G. and Gallagher, F.A. (2022) 'MRI techniques for immunotherapy monitoring', Journal for ImmunoTherapy of Cancer, 10 (9), e004708, pp. 1 - 17. doi: 10.1136/jitc-2022-004708.en_US
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/29409-
dc.descriptionSupplementary materials: supplementary data are available online at: https://jitc.bmj.com/content/10/9/e004708#supplementary-materials .en_US
dc.descriptionCorrection: MRI techniques for immunotherapy monitoring, https://doi.org/10.1136/jitc-2022-004708corr1 . Lau D, Corrie PG, Gallagher FAMRI techniques for immunotherapy monitoring. J Immunother Cancer 2022;10:e004708. doi: 10.1136/jitc-2022-004708. The author Ferdia A Gallagher has had the following affiliation added: Cancer Research UK Cambridge Centre, University of Cambridge.-
dc.description.abstractMRI is a widely available clinical tool for cancer diagnosis and treatment monitoring. MRI provides excellent soft tissue imaging, using a wide range of contrast mechanisms, and can non-invasively detect tissue metabolites. These approaches can be used to distinguish cancer from normal tissues, to stratify tumor aggressiveness, and to identify changes within both the tumor and its microenvironment in response to therapy. In this review, the role of MRI in immunotherapy monitoring will be discussed and how it could be utilized in the future to address some of the unique clinical questions that arise from immunotherapy. For example, MRI could play a role in identifying pseudoprogression, mixed response, T cell infiltration, cell tracking, and some of the characteristic immune-related adverse events associated with these agents. The factors to be considered when developing MRI imaging biomarkers for immunotherapy will be reviewed. Finally, the advantages and limitations of each approach will be discussed, as well as the challenges for future clinical translation into routine clinical care. Given the increasing use of immunotherapy in a wide range of cancers and the ability of MRI to detect the microstructural and functional changes associated with successful response to immunotherapy, the technique has great potential for more widespread and routine use in the future for these applications.en_US
dc.description.sponsorshipDL is supported by a Worldwide Cancer Research Fund (20–0229) and a Cancer Research UK Oxford Centre Development Fund (CRUKDF-DL; C5255/A18085) at the University of Oxford and was a former radiology PhD scholar funded by CRUK (C9685/A25177) and Cambridge Trust at the University of Cambridge on developing immuno-oncology imaging methods and imaging biomarkers of response to cancer immunotherapy. PGC has research funding from CRUK (C7535/A27717), NIHR Efficacy and Mechanism Evaluation (EME NIHR130047) and Pierre Fabre (N/A). FAG has funding from CRUK (C19212/A27150; C19212/A16628), the National Institute of Health Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215–20014), the Cambridge Experimental Cancer Medicine Centre & CRUK Cambridge Centre (C9685/A25177), Addenbrooke’s Charitable Trust (N/A), the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215–20014) and the Cambridge University Hospitals National Health Service (NHS) Foundation.en_US
dc.format.extent1 - 17-
dc.format.mediumElectronic-
dc.languageEnglish-
dc.language.isoenen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.urihttps://doi.org/10.1136/jitc-2022-004708corr1-
dc.rightsCopyright information: © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.titleMRI techniques for immunotherapy monitoringen_US
dc.typeArticleen_US
dc.date.dateAccepted2022-09-06-
dc.identifier.doihttps://doi.org/10.1136/jitc-2022-004708-
dc.relation.isPartOfJournal for ImmunoTherapy of Cancer-
pubs.issue9-
pubs.publication-statusPublished-
pubs.volume10-
dc.identifier.eissn2051-1426-
dc.rights.licensehttps://creativecommons.org/licenses/by/4.0/legalcode.en-
dc.rights.holderAuthor(s) (or their employer(s))-
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright information: © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.2.32 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons